268 related articles for article (PubMed ID: 34727953)
1. Arachidonic acid drives adaptive responses to chemotherapy-induced stress in malignant mesothelioma.
Cioce M; Canino C; Pass H; Blandino G; Strano S; Fazio VM
J Exp Clin Cancer Res; 2021 Nov; 40(1):344. PubMed ID: 34727953
[TBL] [Abstract][Full Text] [Related]
2. HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome.
di Martino S; Amoreo CA; Nuvoli B; Galati R; Strano S; Facciolo F; Alessandrini G; Pass HI; Ciliberto G; Blandino G; De Maria R; Cioce M
Oncogene; 2018 Mar; 37(10):1369-1385. PubMed ID: 29311642
[TBL] [Abstract][Full Text] [Related]
3. Insights into Intra-Tumoral Heterogeneity: Transcriptional Profiling of Chemoresistant MPM Cell Subpopulations Reveals Involvement of NFkB and DNA Repair Pathways and Contributes a Prognostic Signature.
Cioce M; Sacconi A; Pass HI; Canino C; Strano S; Blandino G; Fazio VM
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769499
[TBL] [Abstract][Full Text] [Related]
4. Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma.
Cioce M; Ganci F; Canu V; Sacconi A; Mori F; Canino C; Korita E; Casini B; Alessandrini G; Cambria A; Carosi MA; Blandino R; Panebianco V; Facciolo F; Visca P; Volinia S; Muti P; Strano S; Croce CM; Pass HI; Blandino G
Oncogene; 2014 Nov; 33(46):5319-31. PubMed ID: 24240684
[TBL] [Abstract][Full Text] [Related]
5. SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells.
Canino C; Mori F; Cambria A; Diamantini A; Germoni S; Alessandrini G; Borsellino G; Galati R; Battistini L; Blandino R; Facciolo F; Citro G; Strano S; Muti P; Blandino G; Cioce M
Oncogene; 2012 Jun; 31(26):3148-63. PubMed ID: 22020330
[TBL] [Abstract][Full Text] [Related]
6. Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed.
Cortes-Dericks L; Carboni GL; Schmid RA; Karoubi G
Int J Oncol; 2010 Aug; 37(2):437-44. PubMed ID: 20596671
[TBL] [Abstract][Full Text] [Related]
7. Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation.
Cioce M; Canino C; Goparaju C; Yang H; Carbone M; Pass HI
Cell Death Dis; 2014 Apr; 5(4):e1167. PubMed ID: 24722292
[TBL] [Abstract][Full Text] [Related]
8. 2-Deoxy-glucose Enhances the Effect of Cisplatin and Pemetrexed in Reducing Malignant Pleural Mesothelioma Cell Proliferation But Not Spheroid Growth.
Gerogianni I; Pitaraki E; Jagirdar RM; Kouliou O; Giannakou L; Giannopoulos S; Papazoglou E; Hatzoglou C; Gourgoulianis KI; Zarogiannis SG
Anticancer Res; 2019 Jul; 39(7):3809-3814. PubMed ID: 31262908
[TBL] [Abstract][Full Text] [Related]
9. Mesothelioma-Associated Fibroblasts Modulate the Response of Mesothelioma Patient-Derived Organoids to Chemotherapy via Interleukin-6.
Cioce M; Gatti V; Napolitano F; Giorgiano NM; Marra A; Portella G; Fiorelli A; Pentimalli F; Fazio VM
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791392
[TBL] [Abstract][Full Text] [Related]
10. SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma.
Salaroglio IC; Belisario DC; Bironzo P; Ananthanarayanan P; Ricci L; Digiovanni S; Fontana S; Napoli F; Sandri A; Facolmatà C; Libener R; Comunanza V; Grosso F; Gazzano E; Leo F; Taulli R; Bussolino F; Righi L; Papotti MG; Novello S; Scagliotti GV; Riganti C; Kopecka J
J Exp Clin Cancer Res; 2022 Feb; 41(1):75. PubMed ID: 35197103
[TBL] [Abstract][Full Text] [Related]
11. A STAT3-NFkB/DDIT3/CEBPβ axis modulates ALDH1A3 expression in chemoresistant cell subpopulations.
Canino C; Luo Y; Marcato P; Blandino G; Pass HI; Cioce M
Oncotarget; 2015 May; 6(14):12637-53. PubMed ID: 25868979
[TBL] [Abstract][Full Text] [Related]
12. Tumor-associated macrophage-derived inflammatory cytokine enhances malignant potential of malignant pleural mesothelioma.
Horio D; Minami T; Kitai H; Ishigaki H; Higashiguchi Y; Kondo N; Hirota S; Kitajima K; Nakajima Y; Koda Y; Fujimoto E; Negi Y; Niki M; Kanemura S; Shibata E; Mikami K; Takahashi R; Yokoi T; Kuribayashi K; Kijima T
Cancer Sci; 2020 Aug; 111(8):2895-2906. PubMed ID: 32530527
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of the Efficacy of Pemetrexed Maintenance Therapy in Patients with
Malignant Pleural Mesothelioma].
Zeng X; Jiang Z; Duan J
Zhongguo Fei Ai Za Zhi; 2022 Jan; 25(1):7-13. PubMed ID: 35078279
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines.
Monica V; Lo Iacono M; Bracco E; Busso S; Di Blasio L; Primo L; Peracino B; Papotti M; Scagliotti G
Oncotarget; 2016 Nov; 7(47):76577-76589. PubMed ID: 27391433
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDH(high)CD44(+) phenotype and sphere-forming capacity.
Cortes-Dericks L; Froment L; Boesch R; Schmid RA; Karoubi G
BMC Cancer; 2014 Apr; 14():304. PubMed ID: 24884875
[TBL] [Abstract][Full Text] [Related]
16. JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells.
Zanellato I; Colangelo D; Osella D
Curr Cancer Drug Targets; 2018; 18(8):816-828. PubMed ID: 28669341
[TBL] [Abstract][Full Text] [Related]
17. In Vitro Characterization of Cisplatin and Pemetrexed Effects in Malignant Pleural Mesothelioma 3D Culture Phenotypes.
Papazoglou ED; Jagirdar RM; Kouliou OA; Pitaraki E; Hatzoglou C; Gourgoulianis KI; Zarogiannis SG
Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31569615
[TBL] [Abstract][Full Text] [Related]
18. Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds.
Li Petri G; El Hassouni B; Sciarrillo R; Funel N; Mantini G; Zeeuw van der Laan EA; Cascioferro S; Avan A; Zucali PA; Zaffaroni N; Lagerweij T; Parrino B; Smid K; Deraco M; Granchi C; Braczko A; Smolenski RT; Matherly LH; Jansen G; Assaraf YG; Diana P; Cloos J; Peters GJ; Minutolo F; Giovannetti E
Br J Cancer; 2020 Aug; 123(4):644-656. PubMed ID: 32493992
[TBL] [Abstract][Full Text] [Related]
19. Wnt/IL-1β/IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5.
Milosevic V; Kopecka J; Salaroglio IC; Libener R; Napoli F; Izzo S; Orecchia S; Ananthanarayanan P; Bironzo P; Grosso F; Tabbò F; Comunanza V; Alexa-Stratulat T; Bussolino F; Righi L; Novello S; Scagliotti GV; Riganti C
Int J Cancer; 2020 Jan; 146(1):192-207. PubMed ID: 31107974
[TBL] [Abstract][Full Text] [Related]
20. Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma.
Mairinger FD; Vollbrecht C; Flom E; Christoph DC; Schmid KW; Kollmeier J; Popper HH; Mairinger T; Walter RFH
Oncotarget; 2017 Jun; 8(23):37502-37510. PubMed ID: 28415584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]